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RAPID COMMUNICATION
Tat – Human Immunodeficiency Virus-1 Induces Human Monocyte
Chemotaxis by Activation of Vascular Endothelial Growth Factor
Receptor-1
By Stefania Mitola, Silvano Sozzani, Walter Luini, Luca Primo, Alessandro Borsatti, Herbert Weich,
and Federico Bussolino
Human immunodeficiency virus-1 (HIV-1) Tat protein can be firming the common use of this receptor. Binding studies
performed at equilibrium by using radiolabeled Tat showedreleased by infected cells and activates mesenchymal cells.
Among these, monocytes respond to Tat by migrating into that monocytes expressed a unique class of binding site,
with a kd of approximately 0.2 nmol/L. The binding of radio-tissues and releasing inflammatory mediators. In the present
study, we have examined the molecular mechanism of labeled Tat to monocyte surface and the cross-linking to a
protein of 150 kD was inhibited specifically by an excess ofmonocyte activation by Tat, showing that this viral protein
signals inside the cells through the tyrosine kinase receptor cold Tat or VEGF-A. Western blot analysis with an antibody
anti–VEGFR-1/Flt-1 performed on monocyte phosphopro-for vascular endothelial growth factor encoded by fms-like
tyrosine kinase gene (VEGFR-1/Flt-1). Subnanomolar con- teins immunoprecipitated by an monoclonal antibody anti-
phosphotyrosine showed that Tat induced a rapid phosphor-centrations of Tat induced monocyte chemotaxis, which was
inhibited by cell preincubation with vascular-endothelial ylation in tyrosine residue of the 150-kD VEGFR-1/Flt-1.
Taken together, these results suggest that biologic activitiesgrowth factor-A (VEGF-A). This desensitisation was specific
for VEGF-A, because it not was observed with FMLP. In addi- of HIV-1 Tat in human monocytes may, at least in part, be
elicited by activation of VEGFR-1/Flt-1.tion, the soluble form of VEGFR-1 specifically inhibited polar-
ization and migration induced by Tat and VEGF-A, thus con- q 1997 by The American Society of Hematology.
growth factor),24 we have recently shown that the tyrosineM kinase VEGF receptor-2 (VEGFR-2)28,29 mediates Tat-in-ONOCYTES AND macrophages have been impli-cated in a variety of relevant roles in human human
duced migration of endothelial cells and in vivo angiogene-immunodeficiency virus–type 1 (HIV-1) infection. During
sis.30 VEGF-A is a dimeric glycoprotein mitogenic for endo-the latent phase of the disease, these cells represent an im-
thelial cells and able to induce angiogenesis and vesselportant viral reservoir for the transmission of virus to sensi-
permeability (reviewed in Ferrara et al31 and Kenneth32).tive target cells.1,2 Productive HIV-1 replication in mono-
Two high-affinity tyrosine kinase receptor for VEGF-A havecytes and macrophages is triggered by interleukin-6 (IL-6),3
been identified so far on vascular endothelial cells: VEGFR-granulocyte-macrophage colony-stimulating factor (GM-
1, encoded by the fms-like tyrosine kinase (Flt-1) gene,33CSF),4 lipopolysaccharide (LPS),5 or contact with endothe-
and VEGFR-2, encoded by kinase insert domain-containinglial cells6 and often predicts the clinical manifestation of the
receptor (KDR) gene.28,29 However, the activities of VEGF-disease.2 Furthermore, HIV-1–infected monocytes/macro-
A are not restricted to endothelial cells, because it also acti-phages participate in tissue injury by releasing inflammatory
vates the induction of procoagulant activity by monocytes34cytokines and autacoids.7-9 The mechanism by which HIV-
and their migration by acting through VEGFR-1.35,361 alters monocyte/macrophage gene expression and function
In light of these similarities between Tat and VEGF, weis unknown, and a putative effector is the product of the
have investigated the chemotactic properties of Tat on hu-regulatory viral gene tat. Tat protein transactivates viral
genes, increases the replication rate of virion,10 and regulates
host gene expression, including tumor necrosis factor a and
b (TNF), IL-2, IL-6, major histocompatibility complex of From the Department of Genetics, Biology and Medical Chemis-
try, Torino, Italy; the Mario Negri Institute for Pharmacologicalclass I , IL-2 receptor, p53 tumor-suppressor gene, and super-
Research, Milano, Italy; and the Gesellschaft fuer Biotechologischeoxide dismutase in lymphoid cells11-17 and matrix proteins
Forschung, Braunschweig, Germany.in glioblastoma cells.18
Submitted February 12, 1997; accepted May 22, 1997.Furthermore, Tat can be released by infected cells19 and
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Mononuclear cell preparation. Peripheral blood mononuclearman monocytes. This report shows that monocytes express a
cells (PBMCs) were obtained from buffy coats of healthy bloodhigh-affinity binding site for Tat that induces a rapid (within
donors through the courtesy of Centro Trasfusionale, Ospedale Saccominutes) cell shape change and migration. Monocytes activa-
(Milan, Italy). Blood was washed once with saline at 400g to removetion by Tat is associated to phosphorylation of a 150-kD
plasma and platelets and then centrifuged on Ficoll (Biochrom; Ser-protein that cross-reacted with an anti–VEGFR-1 antibody.
omed, Berlin, Germany) at 600g for 30 minutes at room temperature.Finally, VEGF-A165 cross-desensitized with Tat in chemo- PBMCs were collected at the interface, washed twice with saline,
taxis assay and competed with labeled Tat to monocytes, and resuspended in RPMI 1640 with 1% fetal calf serum (FCS;
suggesting the promiscuous use of a common receptor by Irvine, Santa Ana, CA). In some experiments, monocytes were fur-
the two proteins. ther purified (85% pure) by centrifugation at 450g on a 46% iso-
osmotic Percoll (Pharmacia Biotech) gradient, as previously de-
MATERIALS AND METHODS scribed.37
Migration assay. Cell migration was evaluated using a chemo-Tat protein. Recombinant full-length Tat protein (rTat) was ob-
taxis microchamber technique,38 as previously described,37 using atained by Intracel (London, UK; batch R12.3). rTat (50 ng) gave a
5-mm pore size polycarbonate filter (Neuroprobe, Pleasanton, CA).unique band of 14 kD (12%) detected by silver staining (Gelcode;
Polycarbonate (migrated cell count at the end point) or nitrocellulosePierce, Europe B.V., Oud Beijerland, The Netherlands). Synthetic
(leading front distance as the end point) were used. sTat, rTat,Tat (sTat), constituted by 86 aminoacid residues, was from Tecnogen
VEGF-A165 ,35 and FMLP (Sigma, St Louis, MO) were used as stim-(Piana di Monte Verna, Italy). The purity of this molecule was
uli. Twenty-seven microliters of chemoattractant solution or controlcontrolled by reverse-phase high-pressure liquid chromatography
medium (RPMI 1640 with 0.1% HSA, 1 U/mL heparin) was addedand was more than 97%. sTat was eluted from a Spherisorb C18
to the lower wells of a chemotaxis chamber (Neuroprobe, Bethesda,column (100 1 1 mm; Applied Biosystem, Foster City, CA) for 5
MD). Fifty microliters of cell suspension (1.5 1 106/mL monocytes)minutes under isocratic gradient (100% solvent A: 0.1% trifluoro-
was seeded in the upper chamber. At the end of the incubation (377Cacetic acid in water), for 40 minutes under a linear gradient from
in air with 5% CO2 for 90 minutes), filters were removed and stained0% to 95% solvent B (0.1% trifluoroacetic acid in CH3CN2), for 5
with Diff-Quik (Baxter Spa, Rome, Italy) and five high-power oil-minutes under isocratic gradient (B 95%), and finally for 2 minutes
immersion fields were counted. Cross desensitization studies wereunder linear gradient to 5% solvent B. rTat and sTat were stored at
performed by preincubating cells (2 1 106/mL monocytes in0807C in phosphate-buffered saline (PBS) containing 0.1 % human
PBMCs) with the different agonists at 377C in constant agitation forserum albumin (HSA; Farma Biagini, Lucca, Italy) and 1 mmol/L
30 minutes. The cells were then washed in RPMI 1% FCS, counted,dithiothreitol. To label Tat, rTat (2 mg) was dissolved in 200 mL of
and tested for their ability to respond to agonist stimulation.37 Re-sodium phosphate buffer at 20 mmol/L, pH 7.4, without dithiothrei-
combinant pertussis toxin (PTox) was from Calbiochem (San Diego,tol and transferred in iodogen-coated tubes (50 mg/mL; Pierce),
CA). Cells were preincubated with different concentrations of thewhere Tat was iodinated (5 minutes at 47C) with 0.2 mCi 125I (Amer-
toxins at 377C for 90 minutes. At the end of the incubation, cellssham, Buchs, UK). Twenty microliters of phosphate buffer at 20
were washed twice with RPMI and tested for their ability to migratemmol/L, pH 7.2, containing 1% HSA, 0.4 mol/L NaCl, and 0.1%
in response to chemotactic agonists.37 Ptox treatment did not alterChaps (Pierce) was added, and the reaction products were separated
cell viability (90%) as evaluated by trypan blue dye exclusion.on Sephadex-G10. The specific activity of the tracer was 1 mCi/127
Polarization assay. Monocyte polarization assay was performedfmol. [125I] Tat retained its biologic activity as migration of Kaposi’s
as previously described39 with minor modifications. Briefly, mono-sarcoma cells.34
cytes (106/mL) were prewarmed in polypropilene tubes at 377C forCloning and expression of the soluble form of VEGFR-1/Flt-1.
5 minutes and then exposed to different concentrations of the ago-Human Flt-1 cDNA was cloned from a placental cDNA library.
nists for 10 minutes. The reaction was stopped by adding an equalA 2-kb HindIII fragment of Flt-1 cDNA coding for the first five
volume (1 mL) of ice-cold phosphate-buffered formaldehyde (10%extracellular Ig-like domains was transfected into Spodoptera frugi-
vol/vol; pH 7. 2). The percentage of cells with bipolar configurationperda clone 158 (Sf158) cells using a liposome transfection system
(front-tail) was determined in at least 200 cells for each tube by(Life Technologies GmbH, Eggenstein, Germany) along with puri-
phase-contrast microscopy at 4001 magnification. Each experimentfied and Bsu-36I–linearized baculovirus DNA (Pharmigen, Ham-
was performed in duplicate.burg, Germany). After infection, cells were maintained in serum-
Binding studies. For binding studies, monocytes (1 1 106) werefree medium SF900 II (Life Technologies). Positive baculovirus
incubated for 2 hours at 227C in 0.2 mL RPMI 1640 medium con-plaques were identified by RNA expression of Flt-1. The soluble
taining 20 mmol/L (N-[2-hydroxyethyl]piperazine-N*[2-ethanesul-form of VEGFR-1/Flt-1 (sFlt-1) was purified, initially by addition
fonicacid]) pH 7.4, 0.1% HSA, 0.2 U heparin, 100 mg/mL soybeanof ammonium sulphate to a final concentrations of 35%, and the
trypsin inhibitor, and bacitracin (binding buffer) and 0.7 pmol [I125]-resulting precipitate was discarded and the sFlt-1 in the supernatant
Tat without or with the indicated concentrations of unlabeled poly-was precipitated by the addition of ammonium sulphate to a final
peptides. Alternatively, monocytes were incubated in the same wayconcentration of 65%. After precipitation, the samples were centri-
with different concentrations of [125I]Tat in the presence of 100-foldfuged at 27C. The pellet was dissolved in 10 mmol/L sodium phos-
excess of cold ligand. At the end of incubation, cell suspension werephate buffer (pH 6. 2) containing 0.15 mol/L NaCl and applied to
overlayered on 0.5 mL of dibutylphtalate (Sigma) and centrifugedheparin-Sepharose CL-6B column (1.5 1 4 cm; Pharmacia Biotech,
for 10 minutes at 13,000g, and the pellet was solubilized with 2%Uppsala, Sweden). The column was washed with the same buffer
SDS in PBS was counted in a g counter. Specific binding, whichcontaining 0. 3 or 0.6 mol/L NaCl and sFlt-1 was eluted as a single
was calculated by subtracting from the total the cpm bound afterpeak with 1.2 mol/L NaCl. The purity of the protein was analyzed
incubation with a 100-fold excess of unlabeled ligand, was approxi-using sodium dodecyl sulphate-polyacrilamide gel electrophoresis
mately 80%. The kd was estimated by Scatchard plot using Ligand(SDS-PAGE) under denaturating and nondenaturating conditions
program (Elseviere-Biosoft, Cambridge, UK).and, after silver staining, there appeared a unique band of 70 kD.
Cross-linking. Monocytes (2 1 107) were incubated at 227C inPurified protein was identified by NH2-terminal sequence analysis
0.5 mL of binding buffer with 0.5 nmol/L [125I]Tat with or withoutusing Edman degradation on an automatic gas sequencer (Applied
Biosystems, Weiterstand, Germany). a 50-fold excess of unlabeled rTat or VEGF-A165 for 90 minutes
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and then cross-linked with 1 mmol/L disuccimidyl suberate (Pierce) buffer without detergents, and once with Tris-buffered saline. Pro-
teins were separated by SDS-PAGE (8%), blotted onto nitrocellu-for 30 minutes. Cells were washed twice with PBS and separated
by denaturating SDS-PAGE (8%). Radiolabeled proteins were visu- lose, and probed with polyclonal antibody anti–Flt-1 (Santa Cruz,
Santa Cruz, CA). Immunoreactivity was determined by using thealized by autoradiography.
Tyrosine phosphorylation and immunoprecipitation experiments. enhanced chemiluminescence reaction (Amersham).
Statistical analysis. Chemotaxis experiments were performed inHuman monocytes (1 1 107) were washed three times with RPMI
1640 and then twice with PBS containing 1 mmol/L Na orthovana- triplicate. Results are presented as mean { SD of a representative
experiment or as a mean ({SE) of several experiments. Statisticaldate. Cells were stimulated for different times with rTat (10 ng/mL)
at 47C. At the end of incubation, cells were centrifuged (1 minute significance was assessed using the Student’s t-test.
at 130,000g) and then cells were lysed in 1 mL at 47C in a
20 mmol/L Tris-HCl buffer, pH 7.2, containing 158 mmol/L NaCl,
RESULTS1% Triton X-100, 1% sodium deoxycholate, 1 mmol/L ethylendiami-
netetraacetic acid, 5 mmol/L ethylene glycol-bis(b-aminoethyl Induction of human monocyte migration and polarization
ether)N,N,N*,N* tetracetic acid, and protease and phosphatase inhibi- by Tat. Figure 1A shows that rTat induced a concentration-
tors (50 mg/mL pepstatin, 50 mg/mL leupeptin, 10 mg/mL aprotinin, dependent migration of human monocytes that was statisti-
2 mmol/L phenyl-methyl-sulphonyl fluoride, 500 mg/mL soybean cally significant at the concentration of 1 ng/mL and reached
trypsin inhibitor, 100 mmol/L ZnCl2 , 1 mmol/L Na orthovanadate, maximal values at 10 ng/mL (5 and 500 pmol/L, respec-
1 mmol/L NaF, and 2 mmol/L sodium pirophosphate). After centrif- tively). These concentrations are in the range of the active
ugation (20 minutes for 10,000g), supernatants were precleared by
concentrations described for monocytes26,27 and endothelialincubation for 1 hour with rabbit antimouse IgG-agarose and then
cells.30 At the optimal concentration of 10 ng/mL, the num-incubated for 1 hour with monoclonal antibody 4G10 antiphospho-
ber of monocytes migrating to Tat was 87% { 13% (n tyrosine (10 mg/mL; UBI, Salt Lake City, UT). Immune complexes
3) of that observed in the presence of an optimal (10 nmol/were recovered on rabbit antimouse IgG-agarose. Immunoprecipi-
tates were washed four times with lysis buffer, twice with the same L) concentration of FMLP, a reference chemoattractant. Sta-
Fig 1. Effect of rTat on human monocyte chemotaxis and polarization. (A) Human monocytes (1.5 Ì 106/mL in PBMCs) were tested for
their ability to migrate across a 5-mm pore-size polycarbonate filter in response to different rTat concentrations (l). Results of one experiment
(performed in triplicate and representative of at least 3 independent experiments) are shown. In the same experiment, migration to an optimal
concentration (10 nmol/L) of FMLP was 149 Ô 9 monocytes. **P Ú .001; *P Ú .01 versus control (no rTat) by paired Dunnett’s test. The effect
of Ptox on rTat-induced migration was evaluated by preincubating cells with 1 mg/mL PTox for 90 minutes (s). **P Ú .001 versus respective
Ptox-untreated cells. Results of one experiment (performed in triplicate and representative of at least 3 independent experiments, mean Ô
SD) are shown. (B) Percoll-purified human monocytes (106/mL) were incubated with different concentrations of sTat for 10 minutes (s). The
reaction was stopped and the percentage of cells with bipolar configuration (front-tail) was determined. Data are expressed as the percentage
of increase over control (0%). In the absence of the agonist (control), 23.6% Ô 4% (n ! 3) monocytes were in the polarized configuration.
Results are the mean Ô SD of three independent experiments performed in duplicates. In the same experimental conditions, the effect of 10
nmol/L FMLP was 133% Ô 19% (n ! 3) increase over control. **P Ú .001; *P Ú .01 versus control (no rTat) by paired Dunnett’s test. The effect
of sFlt-1 on rTat-induced polarization was evaluated by preincubating cells with 210 ng/mL for 10 minutes (l). **P Ú .001 versus sFlt-1–
untreated cells. Results of one experiment (performed in triplicate and representative of at least 3 independent experiments, mean Ô SD) are
shown.
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Fig 2. rTat and VEGF-A165 activate human monocytes through the same receptor. (A) Homologous and heterologous desensitization of
monocyte migration by rTat (h), VEGF-A165 (j), and FMLP (
  
  ). Monocytes were preincubated with optimal chemotactic concentrations of the
agonists (10 ng/mL rTat, 10 ng/mL VEGF-A165 , and 10 nmol/L FMLP) at 377C for 30 minutes. The cells were then washed and assayed for their
migration toward homologous of heterologous stimuli used at the same concentrations. Results are expressed as percent of activity with
respect to relative control group (cell incubated with medium and tested against the 4 single agonists). The mean numbers (ÔSE) of three
separate experiments performed in triplicate are reported. (B) Monocyte migration by optimal chemotactic concentrations of the agonists (10
ng/mL rTat and 10 ng/mL VEGF-A165) was evaluated in the absence or in the presence of 210 ng/mL sFlt-1. Results (mean Ô SD) of one
experiment (performed in triplicate and representative of at least 3 independent experiments) are shown. In the same experiment, migration
to an optimal concentration (10 nmol/L) of FMLP was 114 Ô 7 monocytes. *P ! .05 or lower versus rTat or VEGF-A165.
tistical analysis of checkerboard experiments performed with treatment of monocytes with either 10 ng/mL rTat or 10 ng/
mL VEGF-A165 resulted in more than 75% (P  .01 bynitrocellulose filters showed that monocyte migration in re-
sponse to rTat was mainly directional migration (chemo- Dunnett’ test) of inhibition of a subsequent response to the
two agonists. On the contrary, there was no (20% inhibi-taxis), with a minor but consistent chemokinetic component
(data not shown). Boiled rTat was inactive (data not shown). tion) heterologous deactivation between rTat or VEGF-A165
and FMLP (Fig 2A).Identical results were obtained with sTat (data not shown).
Monocytes exposed to rTat or sTat acquired a polarized Of the two VEGF-A165 receptors, human monocytes ex-
press on their surface only VEGFR-1/Flt-1.35,36 The soluble,morphology that was maximal at 10 minutes (data not
shown) and was concentration-dependent, with a peak ob- truncated product of VEGFR-1/Flt-1 (sFlt-1) is a competitor
of VEGF-A37 and has been used to verify the role of thisserved at 10 ng/mL (Fig 1B). These data suggest a direct
effect of rTat on monocyte cytoskeleton reorganization, a receptor on the biologic response of Tat on monocytes. sFlt-1
inhibited both monocyte polarization (Fig 1B) and monocyteprerequisite for cell movement.40 Tat-induced monocyte mi-
gration was sensitive to the action of PTox (Fig 1A and data chemotaxis (Fig 2B) to rTat. The effect was concentration
dependent, with an IC50 of 12 ng/mL for chemotaxis (notnot shown). At the highest concentration tested (1 mg/mL
PTox), monocyte migration to 10 ng/mL rTat was inhibited shown). At the highest concentration of sFlt-1 tested (210
ng/mL), inhibition of chemotaxis to rTat was 71% { 10%79% { 9% (n  3; P  .01; Fig 1A). In the same assay
conditions, chemotaxis to FMLP was inhibited 81% { 7% (n  4; P  .01). In the same experimental conditions,
also monocyte migration to VEGF-A165 was significantly(n  3), as previously reported.37 These data are consistent
with the sensitivity to PTox of most chemotactic agonists,41,42 inhibited (56% { 9%; n  3; P .01), whereas chemotactic
response to FMLP was not affected (120% of control; n including those using tyrosine kinase receptors (ie,
2; not shown). sFlt-1 did not change monocyte basal migra-VEGF-A35165).
tion and boiled sFlt-1 was inactive (Fig 2B). These dataInteraction of Tat with Flt-1 on human monocytes. On
strongly suggest the Tat and VEGF-A165 share common re-the basis of previous observations in endothelial cells,30 the
ceptors on human monocytes.ability of rTat to cross-desensitize with VEGF-A165 in terms
of chemotaxis was investigated. As shown in Fig 2A, pre- To test the presence of high-affinity binding sites for Tat
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Fig 3. Specific binding of [125 I]Tat to monocytes and curve displacement with cold rTat and VEGF-A165. (A) Specific [125I]Tat binding curve
to monocyte at equilibrium and Schatchard analysis. For specific binding studies of Tat, human monocytes (1 Ì 106/ 0.2 mL of binding buffer)
were incubated with increasing concentrations of [125I]Tat in the presence of a 100-fold excess of unlabeled ligand at 227C for 120 minutes. At
the end of incubation, cell suspension were overlayered on 0.5 mL of dibutylphtalate and centrifuged for 10 minutes at 13,000g, and the pellet
was solubilized with 2% SDS in PBS was counted in a g counter. (B) Ligand displacement curve at equilibrium of [125I]Tat binding to monocytes
by rTat and VEGF-A165 . Human monocytes (1 Ì 106) were treated in the same way as in (A) with 0.7 pmol of [125I] without or with the indicated
concentrations of unlabeled rTat (s) or VEGF-A165 (l). Each experiment was repeated at least three times.
on human monocytes, cells were incubated with increasing rTat was inactive, showing the specificity of the phenomenon
(data not shown).concentrations of [125I]Tat in the presence of 100-fold
amounts of cold molecule. The binding evaluated at equilib-
DISCUSSIONrium indicated the presence of a high-affinity binding site
and the calculated kd was 280 { 78 pmol/L (n  3) with Tat protein of HIV-1 activates biologic functions of mes-
320 { 100 receptors per cell (n  3; Fig 3A). As reported enchymal cells, including monocytes and endothelial
in chemotaxis experiments (Fig 2A), VEGF-A165 competed cells.11,13,20,21-27 We have previously shown that Tat binds
with [125I]Tat for the binding to monocytes (Fig 3B), and a VEGFR-2/KDR expressed on endothelial cells and activates
concentration of 100 { 12 pmol/L (n  4) of unlabeled its tyrosine kinase activity.30 Furthermore, antiserum neu-
VEGF-A165 blocked half of the binding of the labeled ligand. tralizing VEGFR-2/KDR or an excess of soluble form of
Figure 3B shows that unlabeled rTat also inhibits the binding KDR inhibited in vitro and in vivo activation of endothelial
of [125I]Tat to monocytes, with a IC50 of 204 { 67 pmol/L. cells triggered by Tat, suggesting that this viral protein mim-
The affinity binding site for Tat was further characterized ics VEGF-A.30
by cross-linking experiments (Fig 4A). Two [125I]Tat-con- Besides migration and proliferation of endothelial
taining major complexes with molecular weights of 92, 163, cells,31,32 VEGF induces directed migration of monocytes
and 180 kD were detected when the ligand was cross-linked and expression of procoagulant activity.34 This effect is me-
to the intact cells and displaced by 50-fold excess of unla- diated by a specific interaction with a single class of binding
beled rTat or VEGF-A165 , indicating the interaction specific- site with an apparent kd of 300 to 500 pmol/L.44 In contrast
ity and the cross-competition between the two polypeptides to endothelial cells, which express both VEGFR-1/Flt-1 and
for the same protein (Fig 4A), confirming the biologic obser- VEGFR-2/KDR,28,29,33 human monocytes express only
vation that VEGF-A165 has a competitive effect on Tat-in- VEGFR-1/Flt-1, which accounts for the observed biologic
duced monocyte movement (Fig 2A). A third complex of activities.35,36
90 to 100 kD was present, but was not displaced by an Indeed, the observations that VEGF-A activates the migra-
excess of cold ligands. tion of monocytes by a specific receptor-dependent mecha-
To further confirm that Tat uses VEGFR-1/Flt-1, we stud- nism31,35,36 and that rTat activates VEGFR-2/KDR in endo-
ied the tyrosine phosphorylation of the receptor after stimula- thelial cells raise the possibility that a VEGFR is also
tion. rTat or VEGF-A165 induced the phosphorylation in essential for the migration and the invasiveness properties
tyrosine residues of a 150-kD protein recognized by of human monocytes triggered by this HIV-1 protein.26,27
Human monocytes stimulated by subnanomolar concen-anti–VEGFR-1/Flt-1 antibody (Fig 4B). Heat-inactivated
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Fig 4. Cross-linking of [125I]Tat to monocytes and effect of rTat on tyrosine autophosphorylation of the VEGFR-1/Flt-1. (A) Monocytes (2 Ì
107) were incubated at 227C in 0.5 mL of binding buffer with 0.5 nmol/L [125I]Tat with or without 50-fold excess of unlabeled rTat or VEGF-A165
for 90 minutes and then cross-linked with 1 mmol/L disuccimidyl suberate for 30 minutes. Solubilized proteins were separated by denaturating
SDS-PAGE (8%) and visualized by autoradiography. (B) Human monocytes (1 Ì 107) were stimulated with rTat (10 ng/mL) in RPMI 1640
medium containing 1 mmol/L Na orthovanadate at 47C. Cell lysates were immunoprecipitated with antiphosphotyrosine monoclonal antibody.
After SDS-PAGE (8%) separation, proteins were immunoblotted with an anti–VEGFR-1/Flt-1 antibody and visualized by enhanced chemilumi-
nescence technique. Each experiment was repeated at least two times.
trations of rTat start to migrate. This biologic effect shows Tat. A third complex of 90 to 100 kD was observed, but not
a cross-desensitization with VEGF-A165 , but not with FMLP. displaced by an excess of cold rTat, suggesting an unspeci-
Furthermore, monocyte migration elicited both by rTat and fied interaction due to the cross-linking procedure. However,
VEGF-A165 is blocked by Ptox, and as a whole these data we cannot exclude that the last complex is the result of a
suggest that the two molecules use an overlapping pathway specific binding with a membrane protein that binds Tat with
to induce monocyte motility. sFlt-1, which lacks in trans- low affinity and high capacity (ie, an integrin45). The lack
membrane and kinase domains and inhibits biologic activi- of displacement of [125I]Tat by the addition of cold rTat
ties of VEGF-A on endothelium,43 has been used to support could be explained by the fact that experimental conditions
this hypothesis. sFlt-1 inhibited the polarization and the mi- have been standardized to study the high-affinity binding
gration induced by rTat and VEGF-A165 , but was ineffective sites
on the activity of FMLP. This suggests that sFlt-1 competes The tyrosine kinase domain of VEGFR-1/Flt-1 is impli-
with membrane spanning VEGFR-1/Flt-1, as shown in endo- cated in the ligand-dependent signal transduction in intact
thelial cells,43 and thus can function as specific antagonist. cells and the same receptor can be weakly phosphorylated
However, it is possible to speculate that sFlt-1 makes a heter- on tyrosine residues upon VEGF-A challenge.33,46,47 There-
odimer with the membrane receptor that cannot signal inside fore, the rapid tyrosine phosphorylation of VEGFR-1/Flt-1
monocytes upon rTat or VEGF-A165 binding. in rTat-stimulated monocytes suggests that the complex Tat/
Based on radioligand binding experiments, monocytes ex- receptor transduces motogenic signals.
pressed a single class of Tat binding sites with a kd of Experimental evidences have indicated that some extracel-
approximately 0.2 nmol/L, similar to that reported for lular activities of Tat can be mediated through specific inter-
VEGF-A on monocytes.43 The displacement of [125I]Tat by actions between the RGD-containing region and integrin re-
an excess of VEGF-A165 again confirms the hypothesis that ceptors.25,27,45,48 Indeed, we cannot exclude a cooperation
Tat uses a VEGFR. [125I]Tat was specifically cross-linked between VEGFR-1/Flt-1 and integrins in monocyte response
into two major complexes with molecular weights of 163 to Tat.
and 180 kD. These complexes were displaced by an excess The data presented in this report suggest that HIV-1-Tat
of Tat or VEGF-A165 . Because the molecular mass of could play an active role in monocyte extravasation and
VEGFR-1/Flt-1 in monocytes is 150 kD (Fig 4), we can subsequent tissue damage in AIDS patients. Furthermore,
speculate that these complexes correspond to VEGFR-1/Flt- the activation of monocyte VEGFR-1/Flt-1 by Tat present
in serum or tissues20,25 could participate to the generalized1 containing, respectively, one and two molecules of labeled
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E, Capitani S, La Placa M: Recombinant human immunodeficiencyimpairment of immune system in infected subjects. A previ-
virus type-1 (HIV-1) Tat protein sequentially up-regulates IL-6 andous report has shown that monocytes from patients with
TGF-b1 mRNA expression and protein synthesis in peripheral bloodAIDS have a selective defect of chemotaxis.49 Our prelimi-
monocytes. Br J Haematol 88:261, 1994nary data demonstrate that Tat desensitizes monocytes to
12. Scala G, Ruocco MR, Ambrosino C, Mallardo M, Giordano
unrelated chemotactic stimuli such as monocyte chemotactic V, Baldassarre F, Dragonetti E, Quinto I, Venuta S: The expressionpeptide-1 (MCP-1; monocytes preincubated for 2 hours in
of the interleukin 6 gene is induced by the human Immunodeficiency
control medium [% over the basal migration; n  3]: Tat virus 1 Tat protein. J Exp Med 179:961, 1994
[10 ng/mL], 75 { 12; VEGF-A165 [10 ng/mL], 72{ 9; MCP- 13. Westendorp MO, Shatrov VA, Schulze-Osthoff K, Frank R,
1 [50 ng/mL], 102 { 15; and monocytes preincubated for 2 Kraft M, Los M, Krammer PH, Droge W, Lehmann V: HIV-1 Tat
potentiates TNF-induced NF-kappa B activation and cytotoxicity byhours with 10 ng/mL rTat [% of the basal migration; n 
altering the cellular redox state. EMBO J 14:546, 19954]: Tat [10 ng/mL],10 { 3; VEGF-A165 [10 ng/mL], 12 {
14. Siekevitz M, Feinberg MB, Holbrook N, Wong-Staal F,2; MCP-1 [50 ng/mL], 15 { 3]) and suggest that continued
Greene WC: Activation of interleukin 2 and interleukin 2 receptorexposure to this viral protein could induce a loss in monocyte
(Tac) promoter expression by the trans-activator (tat) gene productfunctions. We can also presume that Tat-VEGFR-1/Flt-1 in-
of human T-cell leukemia virus, type 1. Proc Natl Acad Sci USAteraction is instrumental in the defective function of profes- 84:5389, 1987
sional antigen-presenting cells, including monocytes, as 15. Buonaguro L, Buonaguro FM, Giraldo G, Ensoli B: The hu-
showed for VEGF-A.50 man immunodeficiency virus type 1 Tat protein transactivates tumor
necrosis factor beta gene expression through a TAR-like structure.
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